Guillian-Barre syndrome.

Area of Science:

• Neurology
• Infectious Diseases
• Immunology

Background:

• Guillian-Barre syndrome (GBS) is a primary cause of acute flaccid paralysis, affecting all age groups but more prevalent in the elderly.
• Campylobacter jejuni, a common cause of bacterial gastroenteritis, is increasingly recognized as a frequent antecedent pathogen for GBS.
• The pathogenesis involves molecular mimicry between microbial epitopes and gangliosides in the Schwann cell membrane.

Purpose of the Study:

• To investigate the association between Campylobacter jejuni infection and Guillian-Barre syndrome.
• To highlight the diagnostic and prognostic factors in GBS.
• To discuss potential preventive strategies for GBS.

Main Methods:

• A prospective case-controlled study design was employed.
• Serological testing for C. jejuni was performed on GBS patients, family controls, and patients with other neurological diseases.
• Clinical diagnosis, supportive care, plasma exchange, and intravenous immunoglobulin therapy were evaluated.

Main Results:

• A high frequency (57%) of positive C. jejuni serology was observed in GBS patients, compared to 8% in family controls and 3% in other neurological disease controls.
• Respiratory failure and autonomic dysfunction are identified as primary causes of mortality in GBS.
• Prognosis is generally good, with 80% of patients achieving full recovery within 3-6 months, though 4% mortality and residual disability occur.

Conclusions:

• Campylobacter jejuni is a significant antecedent pathogen in Guillian-Barre syndrome.
• Supportive care, plasma exchange, and IVIg are crucial for managing GBS and improving outcomes.
• Development of a C. jejuni vaccine could potentially prevent GBS, emphasizing the importance of early and specific diagnosis for favorable outcomes.